People with cystic fibrosis (pwCF) who carry at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or another mutation documented as responsive to ETI, receive ETI therapy. Here, CFTR is linked to cystic fibrosis.